R-spondin-1, human recombinant

$ 91.00

Select Size:

  • RSPO-005, 5 µg91.00
  • RSPO-025, 25 µg291.00
  • RSPO-100, 100 µg991.00
Add to Cart
Sourcehuman 293 cells M.W.25.6 kDa CAS No.
Structural Info
FormulationLyophilized in sterile filtered solution of PBS.
ReconstitutionBefore reconstitution, a brief spin is recommend to drive down any material dislodged from the bottom of the tube. The lyophilized protein should be reconstituted in sterile H2O to a desired concentration.  
StabilityThe lyophilized protein is stable for at least one year if stored at -80 °C. Reconstituted protein is stable for at least four weeks at 4 °C, but should be stored in aliquots at -80 °C for longer term. Avoid repeated freeze and thaw.
PurityGreater than 90% as determined by SDS-PAGE analysis
Biological ActivityThe activity was determined by using a TCF reporter gene assay in cultured human cells. The EC50 ranges from 5 - 20 ng/ml in the presence of 10 ng/mL human WNT-3a.
Country of OriginUSA

R-spondin-1 (RSPO-1) is a natural enhancer of the canonical WNT pathway. When used together with WNT proteins that activate the
beta-catenin pathway, R-spondin-1 enhances the activity of canonical WNT proteins by binding to LGR5 and LGR4 (refs.)
Injection of recombinant R­Spondin-1 into mouse causes  activation of the β­catenin pathway and proliferation of intestinal crypt cells, which forms the basis for a clinical trial in amelioration of chemotherapy-induced colitis.  

The Predicted MW of full-length R-Spondin-1 is 25.6 kDa, and due to glycosylation it runs on SDS­PAGE at ~39 kDa under
reducing conditions. StemRD’s R-Spondin-1 is produced in human 293 cells as a secreted protein (without tag) and purified by a series of chromatography. 

Refs:  de Lau, et al, LGR5 homologues associate with Wnt receptors and mediate R-spondin signaling.  Nature. 2011 July 4; 476: 293;  
Carmon, et al, R-spondins function as ligands for the orphan receptors LGR4 and LGR5 to regulate Wnt/beta-catenin signaling. PNAS. 2011 Jul 12; 108: 11452.

Kawamura M, Miyagawa S, Miki K et al., Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheetsin a porcine ischemic cardiomyopathy model. Circulation. 2012 Sep 11;126(11 Suppl 1):S29-37.